大剂量促红素冲击治疗癌症贫血的临床观察

High-doses Recombinant Human Erythropoietin Pulse therapy on Anemia in Cancers Patients

目的观察大剂量促红素冲击治疗癌症贫血的临床疗效及毒副反应。方法将82例癌症贫血患者随机分为常规剂量组(促红素1万U,每周3次,共6周)与大剂量组(促红素4万U/次,d1、d3、d6、d9、d12、d15),共观察6周,每2周进行1次疗效评价。观察两组患者的有效率、血红蛋白值、输血需求率、停药者比率及药物的不良反应,每2周进行1次疗效评价。结果常规剂量组4周后血红蛋白明显升高,大剂量组治疗2周后血红蛋白明显升高;大剂量组的4周、6周血红蛋白值均高于常规剂量组(P<0.05);大剂量组的2周、4周、6周有效率分别为39.0%、53.6%、75.6%,高于常规剂量组的17.5%、32.5%、50.0%(P<0.05);两组输血需求率及不良反应发生率差异无统计学意义(P>0.05)。结论大剂量促红素冲击治疗癌症贫血的疗效优于常规剂量法,毒副反应无明显增加。

Objective To study the clinical effect and side effect of high-dose recombinant human erythropoietin（rhEPO） therapy on the anemic in cancer patients.Methods The 82 cancer patients with anemic were divided randomly into common-doses group（rhEPO 10 000 U were administered three times weekly for up to 6 weeks） or high-dose group（rhEPO 40 000 U were administered in days 1,3,6,9,12,15）.The efficient,hemoglobin value,blood transfusion demand rate,drug withdrawal rate and adverse reaction of erythropoietin in both groups were observed,and the therapeutic efficacy was evaluated every 2 weeks.Results Hemoglobin level of high-dose group increased significantly after treatment of 2 weeks,while that of common-dose group increased after treatment of 4 weeks.It was higher in high-doses group than those in common-doses group after treatment of 4 and 6 weeks.The effective rates of 2,4 and 6 weeks in large-doses group were 39.0%,53.6% and 75.6%,respectively;and were higher than 17.5%,32.5% and 50.0% in common-doses group,respectively.There were no statistical differences in side effect and transfusion rate between the two groups（P0.05）.Conclusion The clinical effect of high-dose rhEPO is better than common-dose rhEPO on the anemia in cancers patients.There is no difference in side effect between the two methods.